Answers are grounded in this paper and cite their sources.
Glucocorticoids (GCs) are widely prescribed for their anti-inflammatory and pro-apoptotic effects, mediated primarily through the glucocorticoid receptor (GR). However, acquired GC resistance remains a major clinical challenge that compromises therapeutic efficacy. Resistance arises from multilayered barriers along the signaling cascade. At the isoform level, the balance of GR variants with distinct transcriptional properties dictates cellular responsiveness. In the cytoplasm, a “first checkpoint” of chaperones regulates ligand binding, receptor folding, and activation. Beyond this, emerging evidence reveals a nuclear “double-checkpoint,” in which GR transcriptional activity is orchestrated through liquid–liquid phase separation (LLPS) condensates. Within these condensates, dynamic cofactor exchange governs transcriptional precision, while nuclear cofactors such as TRIM24 can lock GR into static hubs, restraining its activity. This review integrates these regulatory layers into a unified framework of GC resistance and highlights potential therapeutic entry points for overcoming this persistent clinical obstacle.
No takes yet. Share an insight, caveat, or question.
A 2025 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: